Good Clinical Practice Guide
Results 1 to 3 of 3

Thread: Reference Safety Information (RSI) - annual updates

  1. #1
    Forum Member
    Join Date
    May 2012

    Reference Safety Information (RSI) - annual updates

    I would be grateful for advice on two points:

    The MHRA website safety reporting (see says that:

    Annual Investigators Brochure (IB) Update
    The Reference Safety Information (RSI) for any Investigational Medicinal Products (IMPs) involved in a clinical trial must stay consistent during each reporting period. At the end of the reporting period the sponsor may assess the new safety information that has been generated and submit any proposed safety changes to the IB or reference safety information as a substantial amendment. This amendment should be supported by the ASR/DSUR and approved before the RSI is changed.

    Changes to the reference safety information include the downgrading of reactions form unexpected to expected. Until the amendment justifying the downgrading has been approved the events must be treated as unexpected.

    • I understood from elsewhere that IB updates were only substantial amendments if they changed the risk/benefit assessment of the trial. Therefore there may be changes to the IB and/or downgrading of reactions from unexpected to expected that do not alter the risk/benefit assessment. Is this contradictory or have I misunderstood something?

    • I sometimes see ctIMPs using licensed medications and the SPC is the RSI. We currently assess expectedness against the current version of the SPC at the time of receipt of the event report. SPC updates are not done to specific timescales and may be updated within reporting periods. How do we handle updates of SPCs? We do not routinely monitor these against the risk/benefit assessment, but should we be doing this? Should we use one version and update the version in use say annually rather than using the version published at the time of event evaluation?

    Thanks for any advice on this.

  2. #2
    I'm afraid I can't answer your questions but I would be very much interested in any response. As a non-commercial CTU based within an NHS Trust, we have similar problems with updating reference safety information and the guidance isn't particularly helpful.

  3. #3
    Similar question. If the Pharmaceutical company have submitted the updated IB to the MHRA (as required) but deem that the changes to the RSI do not affect the risk/benefit assessment of our trial, as does the Chief Investigator, do we, the academic CTU using the IB, still have to submit the changes to the RSI in the IB as a substantial amendment as per the Grey Guide at a cost of 250?

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts